Securities code: 688166 securities abbreviation: Brightgene Bio-Medical Technology Co.Ltd(688166) Announcement No.: 2022-007 Borui biomedical (Suzhou) Co., Ltd
Announcement on the results of share reduction by shareholders holding more than 5%
The board of directors, all directors and relevant shareholders of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law. Important content tips:
Basic information on shareholding of major shareholders
As of the disclosure date of the reduction plan (September 16, 2021), Sequoia Zhisheng equity investment partnership (limited partnership) (hereinafter referred to as “Sequoia Zhisheng”) in Ningbo Meishan free trade port area holds 28724875 shares issued before the initial public offering of A-Shares by Borui biomedical (Suzhou) Co., Ltd. (hereinafter referred to as “the company”), Accounting for 7.0061% of the total share capital of the company; Among them, 8287956 shares were listed and circulated on November 9, 2020, accounting for 2.0215% of the total share capital of the company.
Implementation results of share reduction plan
Sequoia Zhisheng plans to reduce its total holdings of no more than 8287956 shares of the company through centralized bidding or block trading, and the proportion of the shares to be reduced in the total share capital of the company is 2.0215%. If the shares are reduced by means of centralized bidding trading, it shall be implemented within 3 months after 15 trading days from the date of disclosure of the reduction plan; If the shares are reduced by block trading, it shall be implemented within 3 months after 3 trading days from the date of disclosure of the reduction plan. For details, please refer to the announcement on share reduction plan of shareholders holding more than 5% (Announcement No.: 2021-063) disclosed by the company on September 16, 2021.
On January 18, 2022, the company received the notification letter on the implementation of Brightgene Bio-Medical Technology Co.Ltd(688166) share reduction plan issued by Sequoia Zhisheng (hereinafter referred to as “the notification letter”). As of the issuance date of this notification letter, the implementation period of this reduction plan has expired, and Sequoia Zhisheng has reduced 8225074 shares of the company through block trading and centralized bidding trading, accounting for 2.0061% of the total share capital of the company.
1、 Basic information of the reducing entity before the reduction
Shareholder name shareholder identity shareholding number (shares) shareholding proportion current shareholding source
More than 5% of Sequoia Zhisheng is not the largest shareholder, and 7.0061% obtained before IPO: 28724875 shares
The above reduction subjects have no concerted action. 2、 Implementation results of the reduction plan (I) major shareholders disclose the implementation results of the reduction plan due to the following matters: the disclosed reduction time interval expires
Shareholder name number of shares (shares) reduction proportion during the reduction period reduction method reduction price range total amount of reduction (yuan) after the reduction of the current number of shares (yuan / share), the current proportion of shares (shares)
Sequoia Zhisheng 8225074 2.0061% 2021 / 11 / 2 ~ centralized bidding delivery 30.97-37.30 265251068.20 has completed 20499801 4.99995% 2022 / 1 / 18 easy and block transactions
(II) whether the actual reduction is consistent with the previously disclosed reduction plan and commitment √ yes □ no (III) whether the reduction time interval expires and whether the reduction has not been implemented □ not implemented √ implemented
(IV) whether the actual reduction does not reach the minimum reduction quantity (proportion) of the reduction plan □ not reached √ reached (V) whether the reduction plan is terminated in advance □ yes √ no
It is hereby announced.
Board of directors of Borui biomedical (Suzhou) Co., Ltd. January 19, 2022
